Screener Summaries Updates Institutions Sign In More Updates › Mergers & Acquisitions › HOLX Mergers & Acquisitions · Jan 26, 2026
Hologic is supplementing its merger proxy statement to address shareholder litigation alleging disclosure deficiencies… HOLX Hologic Inc
Hologic is supplementing its merger proxy statement to address shareholder litigation alleging disclosure deficiencies regarding its acquisition by Hopper Parent Inc. The filing also updates the company's illustrative equity value range to $66.67–$99.09 per share and notes that a voluntary recall of Brevera 9 Gauge Needles, which accounted for 4.7% of 2025 Breast Health revenue, may negatively impact 2026 contingent value right (CVR) milestones.
More from Hologic Inc Hologic, Inc. has completed its merger with Hopper Parent Inc., becoming a wholly owned subsidiary of the Blackstone… Apr 7, 2026 Hologic, Inc. has received all necessary regulatory approvals to complete its merger with affiliates of Blackstone… Apr 6, 2026 Hologic stockholders approved the merger agreement for the company's acquisition by Blackstone and TPG, receiving… Feb 6, 2026 Hologic, Inc. announced its financial results for the first quarter ended December 27, 2025, via a press release… Jan 29, 2026 Hologic, Inc. announced its financial results for the fourth quarter ended September 27, 2025 Nov 3, 2025 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
